As shown in Table I, β3GnT8 expression was significantly higher in high-grade gliomas (grade III and grade IV) compared to low-grade gliomas (grade I–II) (P<0.05), confirming that β3GnT8 expression is associated with the progression of glioma. This evidence concerns the gene B3GNT8 and central nervous system cancer.